Kudo-Saito C - Search Results

1

Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study).

Shoji H, Kudo-Saito C, Nagashima K, Imazeki H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Muro K, Aoki K, Boku N. Shoji H, et al. Among authors: kudo saito c. J Immunother Cancer. 2024 Nov 3;12(11):e010174. doi: 10.1136/jitc-2024-010174. J Immunother Cancer. 2024. PMID: 39489543 Free article.

2

Prognostic significance of the FSTL1-DIP2A axis in early-stage tongue cancer.

Kudo-Saito C, Matsumura S, Mori T, Honma Y, Yoshimoto S. Kudo-Saito C, et al. Am J Cancer Res. 2024 Aug 25;14(8):3816-3825. doi: 10.62347/RZAO3562. eCollection 2024. Am J Cancer Res. 2024. PMID: 39267678 Free PMC article.

3

Targeting SNCA in the treatment of malignant ascites in gastrointestinal cancer.

Kudo-Saito C, Imazeki H, Ozawa H, Kawakubo H, Hirano H, Boku N, Kato K, Shoji H. Kudo-Saito C, et al. Transl Oncol. 2024 Oct;48:102075. doi: 10.1016/j.tranon.2024.102075. Epub 2024 Aug 3. Transl Oncol. 2024. PMID: 39098214 Free PMC article.

4

CRP and soluble CTLA4 are determinants of anti-PD1 resistance in gastrointestinal cancer.

Oshima K, Shoji H, Boku N, Hirano H, Okita N, Takashima A, Kato K, Kudo-Saito C. Oshima K, et al. Among authors: kudo saito c. Am J Cancer Res. 2024 Mar 15;14(3):1174-1189. doi: 10.62347/NQBL9998. eCollection 2024. Am J Cancer Res. 2024. PMID: 38590413 Free PMC article.

5

IL25⁺ macrophages are a key determinant of treatment resistance of IL17RB⁺ breast cancer.

Ozaki Y, Kinowaki K, Kawabata H, Kudo-Saito C. Ozaki Y, et al. Among authors: kudo saito c. Am J Cancer Res. 2023 Oct 15;13(10):4931-4943. eCollection 2023. Am J Cancer Res. 2023. PMID: 37970362 Free PMC article.

6

Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer.

Kudo-Saito C, Boku N, Hirano H, Shoji H. Kudo-Saito C, et al. Front Immunol. 2022 Sep 23;13:1009701. doi: 10.3389/fimmu.2022.1009701. eCollection 2022. Front Immunol. 2022. PMID: 36211375 Free PMC article. Review.

7

Blocking FSTL1 boosts NK immunity in treatment of osteosarcoma.

Ogiwara Y, Nakagawa M, Nakatani F, Uemura Y, Zhang R, Kudo-Saito C. Ogiwara Y, et al. Among authors: kudo saito c. Cancer Lett. 2022 Jul 1;537:215690. doi: 10.1016/j.canlet.2022.215690. Epub 2022 Apr 16. Cancer Lett. 2022. PMID: 35439537

8

Targeting AURKA in treatment of peritoneal tumor dissemination in gastrointestinal cancer.

Ozawa H, Imazeki H, Ogiwara Y, Kawakubo H, Fukuda K, Kitagawa Y, Kudo-Saito C. Ozawa H, et al. Among authors: kudo saito c. Transl Oncol. 2022 Feb;16:101307. doi: 10.1016/j.tranon.2021.101307. Epub 2021 Dec 10. Transl Oncol. 2022. PMID: 34902741 Free PMC article.

9

CD11b⁺DIP2A⁺LAG3⁺ cells facilitate immune dysfunction in colorectal cancer.

Kudo-Saito C, Ogiwara Y, Imazeki H, Boku N, Uemura Y, Zhang R, Kawano-Nagatsuma A, Kojima M, Ochiai A. Kudo-Saito C, et al. Am J Cancer Res. 2021 Nov 15;11(11):5428-5439. eCollection 2021. Am J Cancer Res. 2021. PMID: 34873470 Free PMC article.

10

CD11b⁺CTLA4⁺ myeloid cells are a key driver of tumor evasion in colorectal cancer.

Imazeki H, Ogiwara Y, Kawamura M, Boku N, Kudo-Saito C. Imazeki H, et al. Among authors: kudo saito c. J Immunother Cancer. 2021 Jul;9(7):e002841. doi: 10.1136/jitc-2021-002841. J Immunother Cancer. 2021. PMID: 34261702 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

40 results

Search Page

Filters